Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for Janus kinase inhibitors
Most Correlated Studies
- B-cell lymphoma cell lines treated by 92 FDA approved compounds - a timecourse
- Epithelial cells from small airway treated with interferons, Baricitinib or Ruxolitinib
- Ovarian cancer model treated with JAK inhibitor AZD1480
- CD4+ T cells activated under Th0 conditions with or without tofacitinib
- White-to-brown metabolic conversion of adipocytes by JAK inhibition
Most Relevant Literature
- In vitro JAK kinase activity and inhibition assays.
- In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
- JAK2 the future: therapeutic strategies for JAK-dependent malignancies.
- Janus kinase inhibitors as a new therapeutic principle].
- Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthri…
Most Relevant Clinical Trials
- Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis
- Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoi…
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
- Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8…
- Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Infl…
